Arachidonyl-2'-chloroethylamide

Arachidonyl-2'-chloroethylamide (ACEA) is a synthetic agonist of the CB1 receptor. It is used in scientific research to study the function of the CB1 receptor, particularly in relation to pain, emotion, appetite, and neuroprotection.

Chemistry[edit | edit source]

ACEA is a derivative of arachidonic acid, a polyunsaturated omega-6 fatty acid. It is synthesized by the addition of a 2-chloroethylamide group to the arachidonic acid molecule. The resulting compound is a potent and selective agonist for the CB1 receptor, with a binding affinity that is comparable to that of the endogenous cannabinoid anandamide.

Pharmacology[edit | edit source]

ACEA acts as a full agonist at the CB1 receptor, meaning it can fully activate the receptor in the absence of other ligands. This distinguishes it from partial agonists, which can only partially activate the receptor, and antagonists, which prevent the receptor from being activated.

The CB1 receptor is primarily found in the central nervous system, where it plays a role in a variety of physiological processes. Activation of the CB1 receptor by ACEA can produce a range of effects, including analgesia, sedation, appetite stimulation, and neuroprotection.

Research[edit | edit source]

ACEA has been used in a variety of research contexts to study the function of the CB1 receptor. For example, it has been used to investigate the role of the CB1 receptor in pain perception, with studies suggesting that activation of the receptor can produce analgesic effects.

ACEA has also been used to study the role of the CB1 receptor in neuroprotection. Research has suggested that activation of the CB1 receptor can protect neurons from damage in conditions such as stroke and traumatic brain injury.